http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
IsoRay Announces Preliminary Second Quarter F2018 Revenue of $1.54 Million, 50% Year-over-Year Increase
-
IsoRay (ISR) Announces Case Report Publication Discussing Focal Radiation Treatment of Brain Metastases with Cesium-131
-
IsoRay Announces Case Report Publication Discussing Focal Radiation Treatment of Brain Metastases with Cesium-131
-
IsoRay Announces Manufacturing and Supply Agreement with GT Medical Technologies for GammaTile™ Radiation Therapy System
-
IsoRay Announces Manufacturing and Supply Agreement with GT Medical Technologies for GammaTile™ Radiation Therapy System
-
IsoRay Announces First Quarter Fiscal 2018 Financial Results
-
IsoRay, Inc. Announces the Launch of a Phase II, Multicenter Clinical Trial with Cesium-131 Adjuvant Radiation for Retroperitoneal Sarcoma Delivery System (CARDS Trial) by University of Louisville, Di
-
IsoRay Announces First Quarter Fiscal 2018 Earnings Conference Call
-
IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase
-
IsoRay (ISR) Says Study Accepted for Publication in International Journal of Radiation Oncology, Biology, Physics
-
IsoRay Announces Study Accepted for Publication in the International Journal of Radiation Oncology, Biology, Physics entitled "Re-irradiation using Permanent Interstitial Brachytherapy (PIB): A P
-
IsoRay (ISR) Announces Poster Presentation at ASTRO Conf.
-
IsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual Am
-
IsoRay Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
-
IsoRay (ISR) Reports Prelim. Q4 Revenue of $1.37M
-
IsoRay Announces Preliminary Fourth Quarter F2017 Revenue of $1.37 Million, 22% Year-over-Year Increase
-
New Study Shows Brachytherapy And Cesium-131 Isotope Treatment Beneficial For Prostate Cancer Patients
-
IsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer
-
IsoRay Receives FDA Response to 510(k) Application for GammaTile™
-
IsoRay (ISR) Reports Published Study on the Impact of Permanent Low-Dose Rate Cesium-131 Brachytherapy on Local Control & Radionecrosis in Patients Treated for Large Brain Metastases
-
IsoRay Announces Study Published in The International Journal of Radiation Oncology, Biology, Physics entitled, "Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection a
-
IsoRay Announces Third Quarter Fiscal 2017 Financial Results
-
IsoRay (ISR) Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics
-
IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled "Long-term Quality of Life in Prostate Cancer Patients Treated with C
-
IsoRay (ISR) Announces Final Court Approval of Class Action Settlement
-
IsoRay Announces Final Court Approval of Class Action Settlement
-
IsoRay Announces Second Quarter Fiscal 2017 Financial Results
-
MicroCap Review Magazine Winter/Spring 2017 Issue Now Available
-
IsoRay Medical, Inc. Discusses Cesium-131 and its Applications in New SNNLive Video Interview on StockNewsNow.com
-
IsoRay (ISR) Reports Launch of Pilot Study Investigating Role of Cesium-131 in Management of Recurrent Head and Neck Cancer
-
IsoRay, Inc. Announces the Launch of a Pilot Study Using Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Resectable High Risk Recurrent Head and Neck Cancer by Case Comp
-
IsoRay to Present at 9th Annual LD Micro Investor Conference
-
IsoRay (ISR) Announces Presentation on Cs-131 Brachytherapy in Recurrent High Grade Glioma
-
IsoRay Announces "Cesium-131 Brachytherapy for Salvage of Recurrent High Grade Glioma" Poster Presentation at 21st Annual Scientific Meeting of Society for Neuro-Oncology
-
IsoRay Announces First Quarter Fiscal 2017 Financial Results
-
IsoRay, Inc. Announces Date for Fiscal 2017 Annual Meeting and Shareholder Record Date
-
IsoRay, Inc. Announces Launch of Newly Redesigned Patient and Clinician Focused Corporate Website
-
IsoRay (ISR) Enters Class Action Stipulation of Settlement
-
IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation
-
IsoRay Announces Fourth Quarter and Year End Fiscal 2016 Financial Results
-
IsoRay Announces Fourth Quarter and Year End Fiscal 2016 Financial Results
-
IsoRay, Inc. to Present at Rodman & Renshaw 18th Annual Global Investment Conference
-
IsoRay (ISR) Announces Presentation of Encouraging Cesium-131 Data in Gynecologic Cancer Patients
-
Women's Cancer and Cesium-131 Treatments: Topic of Two Presentations at the 2016 Annual Meeting of the American Brachytherapy Society and World Congress of Brachytherapy
-
IsoRay (ISR) Announces Presentation of Positive Cesium-131 Brachytherapy Data at SNO Conference
-
IsoRay® Announces Results of Prospective Trial Presented at Society of Neuro-Oncology Conference
-
IsoRay's (ISR) Motion to Dismiss Securities Suit Denied by Court
-
Court Issues Ruling on IsoRay Motion to Dismiss Securities Lawsuit
-
IsoRay Provides Update on Motion to Dismiss Securities Lawsuit
-
IsoRay Announces Third Quarter Fiscal 2016 Financial Results and Early Conclusions from Ongoing Strategic Review Process

